Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
Status: | Terminated |
---|---|
Conditions: | Alzheimer Disease, Parkinsons Disease, Neurology, Psychiatric |
Therapuetic Areas: | Neurology, Psychiatry / Psychology |
Healthy: | No |
Age Range: | 50 - Any |
Updated: | 3/29/2019 |
Start Date: | October 20, 2016 |
End Date: | January 17, 2019 |
An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder
This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the
treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder
(RBD) in subjects with Lewy body dementia (LBD).
treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder
(RBD) in subjects with Lewy body dementia (LBD).
This is a multi-center open-label, long-term study in LBD subjects with RBD and/or VHs.
Eligible subjects who completed a previous nelotanserin VH or RBD study and choose to
participate in this open-label study will receive 20, 40, 60, or 80 mg nelotanserin once
daily for 24 weeks.
Eligible subjects who completed a previous nelotanserin VH or RBD study and choose to
participate in this open-label study will receive 20, 40, 60, or 80 mg nelotanserin once
daily for 24 weeks.
Inclusion Criteria:
- Subjects with LBD who completed a previous nelotanserin VH or RBD study
Exclusion Criteria:
- Subjects with a current serious and/or unstable cardiovascular, respiratory, thyroid,
gastrointestinal, renal, hematologic or other medical disorder
We found this trial at
19
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials